EUVIMEDEUVIMED entdecken
Crossref

Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study

Buket Şahin Çelik, Selim Giray Nak

Annals of Clinical and Analytical Medicine · 01.11.2026 · 17 (11) · 1162-1166

DOI: 10.4328/acam.50010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Analytical Medicine, erschienen am 01.11.2026. Verfasst von Buket Şahin Çelik und 1 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tumor necrosis factor (TNF) plays a pivotal role in the immunopathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate treatment response, treatment-related complications, and clinical outcomes in patients with IBD receiving anti-TNF therapy, specifically infliximab and adalimumab.

Methods

This retrospective study included 117 patients with IBD who received anti-TNF therapy between January 2012 and May 2017 and were followed at a unıversity gastroenterology department. Treatment responses (complete remission, partial remission, non-response, and death), treatment-related complications, and clinical outcomes were assessed using electronic medical records.

Results

The median age was 37.5 years (range: 20–77) in patients with Crohn’s disease and 38 years (range: 22–70) in patients with ulcerative colitis (UC). Male predominance was observed in both groups. Infliximab, adalimumab, or both agents were used in 34.0%, 51.1%, and 14.9% of UC patients, and in 45.7%, 34.3%, and 20.0% of Crohn’s disease patients, respectively. The overall response rate to anti-TNF therapy was 69.6%, with response rates of 75.0% in Crohn’s disease and 61.7% in UC. No significant differences were observed between infliximab and adalimumab or between monotherapy and combination therapy.

Conclusion

Anti-TNF therapy was effective and well-tolerated in both Crohn’s disease and ulcerative colitis. Treatment response was independent of demographic and disease-related factors, while secondary non-response was more common than primary non-response.

Zitieren

APA

Çelik, B. Ş., & Nak, S. G. (2026). Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study. Annals of Clinical and Analytical Medicine, 17(11), 1162-1166. https://doi.org/10.4328/acam.50010

Vancouver

Çelik BŞ, Nak SG. Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study. Annals of Clinical and Analytical Medicine. 2026;17(11):1162-1166. doi:10.4328/acam.50010

BibTeX
@article{elik2026,
  author = {Çelik, Buket Şahin and Nak, Selim Giray},
  title = {Retrospective analysis of anti-TNF therapy in inflammatory bowel diseases: a single-center retrospective study},
  journal = {Annals of Clinical and Analytical Medicine},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1162--1166},
  doi = {10.4328/acam.50010}
}
Kostenlos starten →